Course

Common Comorbidities in Rheumatology

Common comorbidities that exist in our patients with rheumatological diseases can be a challenge. It is essential to know the risks associated, disease states, and treatment regimens to provide safe and effective care, as well as communicate these risks with your patients and their caregivers. This session will include screenings used to monitor cardiovascular issues, ILD, osteoporosis, depression, stroke, and cancers.

0 out of 3 steps completed0%
0 Lessons

Course Summary

The 2020 Pacific Coast Rheumatology Forum Enduring Course consists of a series of videos from passionate experts presented at the 2020 Pacific Coast Rheumatology Forum in Manhattan Beach, California. In this series, participants will learn the most up-to-date discoveries of autoimmune diseases, the latest in treatment guidelines, and effective clinical skills to increase their practice’s efficiency. Following your participation with this course, you will have sharpened your skills and knowledge in order to provide the necessary support and treatments for your patients. This course is titled “Common Comorbidities in Rheumatology.” To receive CNE credit, participants must complete the course, evaluation, and post-test. A certificate of completion will be automatically generated following the completion of the course.

Faculty

Linda Grinnell-Merrick, MS, NP-BC
University of Rochester Medical Center

Target Audience

The target audience for the forum includes registered nurses (RNs), nurse practitioners (NPs), physician assistants (PAs), and other healthcare professionals who are engaged in clinical practice, education, research, and advocacy for the care of adult and pediatric patients with rheumatic diseases.

Learning Objectives

  • Identify common comorbidities seen in RA, PSA, and SLE
  • Understand the role that inflammation plays in RA, PSA, and SLE comorbidities
  • Identify possible treatments for the management of comorbidities

Accreditation Statement

The Rheumatology Nurses Society is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation (Provider No. P0500).

Participants will earn .75 continuing nursing contact hour by actively participating in education and completing an online evaluation upon completion of program.

Faculty Disclosures

According to the disclosure policy of the Rheumatology Nurses Society, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relevant relationships with any commercial interests related to this activity. The existence of these interests or relationships is not viewed as implying bias or decreasing the value of the presentation. All educational materials are reviewed for fair balance, scientific objectivity and levels of evidence.

Disclosures are as follows:

Linda Grinnell-Merrick, MS, NP-BC
Speakers Bureau: Celgene, Janssen, AbbVie, Novartis, Sanofi
Consultant: Janssen, Novartis, Sandoz, AbbVie, Pfizer

Cathy Patty-Resk, MSN, RN-BC, CPNP-PC, Planning Committee
Advisory Board: Novartis, Sandoz, Inc.

Kevin Lyons, Executive Director of the Rheumatology Nurses Society
Nothing to disclose

Kim Cheramie, MSN, RN-BC, Lead Nurse Planner
Nothing to disclose

Method of Participation

There are no fees to participate in the activity. Participants must review the activity information including the learning objectives and disclosure statements, as well as the content of the activity. To receive CNE contact hours for your participation, please complete the post-test (achieving a passing grade of 75% or greater), and program evaluation. Your certificate can be printed immediately.

Copyright Statement

© 2020. This CNE-certified activity is held as copyrighted © by Rheumatology Nurses Society. Through this notice, the Rheumatology Nurses Society grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).